Monopar Therapeutics Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Monopar Therapeutics quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • Monopar Therapeutics Debt-to-equity for the quarter ending September 30, 2024 was 22.4 %, a 28.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 22.4 -8.96 -28.5% Sep 30, 2024
Q2 2024 24.3 -2.26 -8.51% Jun 30, 2024
Q1 2024 27.9 +5.8 +26.2% Mar 31, 2024
Q4 2023 31.5 +16 +103% Dec 31, 2023
Q3 2023 31.4 +20.5 +189% Sep 30, 2023
Q2 2023 26.6 +18 +210% Jun 30, 2023
Q1 2023 22.1 +15.9 +254% Mar 31, 2023
Q4 2022 15.5 Dec 31, 2022
Q3 2022 10.9 Sep 30, 2022
Q2 2022 8.56 Jun 30, 2022
Q1 2022 6.24 Mar 31, 2022
Q4 2020 5.08 -2.93 -36.6% Dec 31, 2020
Q3 2020 4.54 -4.07 -47.3% Sep 30, 2020
Q2 2020 5.5 -1.43 -20.6% Jun 30, 2020
Q1 2020 6.1 +0.41 +7.21% Mar 31, 2020
Q4 2019 8.01 +3.8 +90.3% Dec 31, 2019
Q3 2019 8.61 +4.99 +138% Sep 30, 2019
Q2 2019 6.93 Jun 30, 2019
Q1 2019 5.69 Mar 31, 2019
Q4 2018 4.21 Dec 31, 2018
Q3 2018 3.62 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.